Peripheral neuropathic pain -: a multidimensional burden for patients

被引:169
|
作者
Meyer-Rosberg, K
Kvarnström, A
Kinnman, E
Gordh, T
Nordfors, LO
Kristofferson, A
机构
[1] Astra Pain Control AB, SE-15185 Sodertalje, Sweden
[2] Univ Uppsala Hosp, Dept Anesthesiol & Intens Care, Acad Hosp, SE-75105 Uppsala, Sweden
[3] Danderyd Hosp, Dept Anesthesiol & Intens Care, SE-18288 Stockholm, Sweden
关键词
peripheral neuropathic pain; peripheral nerve injury; nerve root lesion; SF-36; Nottingham Health Profile; health related quality of life; rating scale;
D O I
10.1053/eujp.2001.0259
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The present study was undertaken to assess the health-related quality of life (HRQoL) and burden of illness due to pain and its treatment for patients with peripheral neuropathic pain (PNP). It is the first step in finding reliable instruments/targets to evaluate treatment outcome in this patient population. Study population consisted of 126 patients suffering from neuropathic, pain due to a peripheral nerve or root lesion, recruited from two multidisciplinary pain clinics. HRQoL was examined using Short Form 36 (SF-36) Health Survey and Nottingham Health Profile (NHP). Pain intensity in four categories (at rest and evoked by movement, touch and cold) was rated on a visual analogue scale (VAS). Degree of discomfort from pain and 25 symptoms related to pain and side-effects was also assessed. Reduction in workload due to pain was recorded, as was the pain relief from previous and current treatments and the reasons for discontinuing previous treatments. All dimensions in SF-36 and NHP were significantly impaired. SF-36 was a valid instrument for describing the impact of pain on the HRQoL of patients with PNP. NHP had a lower reliability but has other advantages that might be of importance. Many patients experienced poor pain relief from ongoing pain treatments. Most previous treatments were discontinued owing to lack of efficacy and/or severe side-effects. Many patients experienced a high intensity of at least one type of pain; median VAS for the highest pain intensity score of each patient (any type of pain) was 74/100. Besides pain, patients were most bothered by difficulty in sleeping, lack of energy, drowsiness, difficulty in concentrating and dry mouth. Employment status was reduced owing to pain in 52% of the patients. The intense pain, other troublesome symptoms, limited efficacy and tolerability of available treatments, together with the impaired health and reduced work status, amount to a substantial burden for patients with PNP. (C) 2001 European Federation of Chapters of the International Association for the Study of Pain.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 50 条
  • [41] Cardiovascular safety profile of duloxetine in patients with diabetic peripheral neuropathic pain
    Kajdasz, Daniel K.
    Walker, Daniel J.
    Raskin, Joel
    Wernicke, Joachim F.
    DIABETES, 2006, 55 : A138 - A138
  • [42] Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Skljarevski, Vladimir
    Desaiah, Durisala
    Zhang, Qi
    Chappell, Amy S.
    Detke, Michael J.
    Gross, Jorge L.
    Ziegler, Dan
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2009, 25 (07) : 623 - 631
  • [43] Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
    Skljarevski, V.
    Desaiah, D.
    Zhang, Q.
    Chappell, A. S.
    Detke, M. J.
    Gross, J. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 163 - 164
  • [44] Comparing objective cognitive impairments in patients with peripheral neuropathic pain or fibromyalgia
    Jacobsen, Henrik Borsting
    Stiles, Tore C.
    Stubhaug, Audun
    Landro, Nils Inge
    Hansson, Per
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] Comparing objective cognitive impairments in patients with peripheral neuropathic pain or fibromyalgia
    Henrik Børsting Jacobsen
    Tore C. Stiles
    Audun Stubhaug
    Nils Inge Landrø
    Per Hansson
    Scientific Reports, 11
  • [46] Burden of neuropathic pain on quality of life in the United States: BEAT neuropathic pain observational study
    Sadosky, A.
    Schaefer, C.
    Mann, R.
    Daniel, S.
    Parsons, B.
    Bergstrom, F.
    Nieshoff, E.
    Tuchman, M.
    Nalamachu, S.
    Anschel, A.
    Stacey, B.
    JOURNAL OF PAIN, 2013, 14 (04): : S31 - S31
  • [47] Long term clinical outcome of peripheral nerve stimulation in patients with chronic peripheral neuropathic pain
    Van Calenbergh, Frank
    Gybels, Jan
    Van Laere, Koen
    Dupont, Patrick
    Plaghki, Leon
    Depreltere, Bart
    Kupers, Ron
    SURGICAL NEUROLOGY, 2009, 72 (04): : 330 - 335
  • [48] The relationships between sleep and pain in patients with diabetic peripheral neuropathic pain: Responses to treatment with duloxetine
    Fishbain, D. A.
    Hall, J.
    Meyers, A.
    Gonzales, J.
    Whitmyer, V.
    Thompson, H.
    Skljarevski, V.
    Mallinckrodt, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 270 - 270
  • [49] Modeling the Predictive Value of Pain Intensity on Costs and Resources Utilization in Patients With Peripheral Neuropathic Pain
    Perez, Concepcion
    Navarro, Ana
    Saldana, Maria T.
    Wilson, Koo
    Rejas, Javier
    CLINICAL JOURNAL OF PAIN, 2015, 31 (03): : 273 - 279
  • [50] MODELLING THE PREDICTIVE VALUE OF PAIN INTENSITY ON COSTS AND RESOURCES UTILIZATION IN PATIENTS WITH PERIPHERAL NEUROPATHIC PAIN
    Perez, C.
    Navarro, A.
    Saldana, M. T.
    Wilson, K.
    Rejas, J.
    VALUE IN HEALTH, 2013, 16 (07) : A382 - A382